|
|
Volumn 492, Issue 7429 SUPPL, 2012, Pages
|
|
Silencing psoriasis
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ALEFACEPT;
AN 2728;
ANTIPSORIASIS AGENT;
APREMILAST;
BRIAKINUMAB;
BRODALUMAB;
CNT 1959;
CNTO 1959;
EFALIZUMAB;
ETANERCEPT;
INFLIXIMAB;
INTERLEUKIN 17 ANTIBODY;
IXEKIZUMAB;
MK 3222;
PHOSPHODIESTERASE IV INHIBITOR;
SECUKINUMAB;
TOFACITINIB;
UNCLASSIFIED DRUG;
USTEKINUMAB;
DERMATOLOGICAL AGENT;
DRUG DERIVATIVE;
HYBRID PROTEIN;
INTERLEUKIN 17;
MONOCLONAL ANTIBODY;
PYRIMIDINE DERIVATIVE;
PYRROLE DERIVATIVE;
THALIDOMIDE;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL (TOPIC);
COST BENEFIT ANALYSIS;
DISEASE SEVERITY;
DRUG COST;
DRUG EFFICACY;
DRUG SAFETY;
DRUG WITHDRAWAL;
GENE EXPRESSION;
HUMAN;
NOTE;
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;
PSORIASIS;
UNSPECIFIED SIDE EFFECT;
ARTICLE;
DRUG ANTAGONISM;
GENETICS;
IMMUNOLOGY;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS AS TOPIC;
DERMATOLOGIC AGENTS;
HUMANS;
INTERLEUKIN-17;
PSORIASIS;
PYRIMIDINES;
PYRROLES;
RECOMBINANT FUSION PROTEINS;
THALIDOMIDE;
|
|
EID: 84871770232
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/492S58a Document Type: Note |
|
Times cited : (26)
|
|
References (7)
|
